Nested has developed a platform that maps mutations and leverages artificial intelligence to predict protein structures and reveal binding pockets formed when proteins assemble into complexes. The company is advancing a pipeline of small‑molecule cancer drugs built from those structural insights; its lead program, NEST‑1, is a molecular glue targeting the RAS/MAPK pathway. Preclinical data show NEST‑1 can cross the blood‑brain barrier, and Nested envisions its molecules as potential combination partners with other therapies. The startup was incubated within Versant Ventures and is led by CEO Darrin Miles with Klaus Hoeflich as chief scientific officer; scientific co‑founders include Arvin Dar and Kevan Shokat. Nested has four programs and plans to use the new capital to advance its two lead programs into clinical testing, aiming for a development candidate from the lead program in Q1 next year to seek FDA permission to begin trials. The company’s stated platform goal is to produce at least one investigational new drug application per year.

Total raised

$90M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2022